Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics

Association Non-Profit F.I.R.S.Thermae (Interdisciplinary Training, Researches and Spa Sciences) in Italian National Register of Research of MIUR, Naples, 80070 Bacoli, Italy

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Biomolecules 2020, 10(12), 1672; https://doi.org/10.3390/biom10121672

Received: 15 November 2020 / Revised: 8 December 2020 / Accepted: 12 December 2020 / Published: 14 December 2020

(This article belongs to the Special Issue Pathogenesis of Arthritis)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease that is very complex and heterogeneous. If not adequately treated, RA patients are likely to manifest excess of morbidity and disability with an important impact on the quality of life. Pharmacological treatment is based on the administration of the disease-modifying antirheumatic drugs (DMARDs), subdivided into conventional synthetic (csDMARDs), targeted synthetic (tsDMARDs), and biological (bDMARDs). bDMARDs are now frequently administered in patients, both as alternative treatment and together with csDMARDs. Unfortunately, there is a therapeutic response variability both to old and new drugs. Therefore, to identify pre-therapeutic and on-treatment predictors of response is a priority. This review aims to summarize recent advances in understanding the causes of the variability in treatment response in RA, with particular attention to predictive potential of autoantibodies and DMARD pharmacogenetics. In recent years, several biomarkers have been proposed to personalize the therapy. Unfortunately, a magic bullet does not exist, as many factors concur to disease susceptibility and treatment outcomes, acting around the patient’s congenital background. Models integrating demographic, clinical, biochemical, and genetic data are needed to enhance the predictive capacity of specific factors singularly considered to optimize RA treatment in light of multidisciplinary patient management. View Full-Text

Keywords: autoimmune disorder; pharmacogenetics; methotrexate; disease-modifying antirheumatic drugs; autoantibodies

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Share and Cite

MDPI and ACS Style

Conti, V.; Corbi, G.; Costantino, M.; De Bellis, E.; Manzo, V.; Sellitto, C.; Stefanelli, B.; Colucci, F.; Filippelli, A. Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics. Biomolecules 2020, 10, 1672. https://doi.org/10.3390/biom10121672

AMA Style

Conti V, Corbi G, Costantino M, De Bellis E, Manzo V, Sellitto C, Stefanelli B, Colucci F, Filippelli A. Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics. Biomolecules. 2020; 10(12):1672. https://doi.org/10.3390/biom10121672

Chicago/Turabian Style

Conti, Valeria, Graziamaria Corbi, Maria Costantino, Emanuela De Bellis, Valentina Manzo, Carmine Sellitto, Berenice Stefanelli, Francesca Colucci, and Amelia Filippelli. 2020. "Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics" Biomolecules 10, no. 12: 1672. https://doi.org/10.3390/biom10121672

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI